Health Condition 1: J309- Allergic rhinitis, unspecified
Conditions
Interventions
Intervention1: Diethylcarbamazine 100 mg twice a day after food for 21 days
along with
Montelukast 10mg and fexofenadine 120mg once a day at night combination for 14 days: Tablet Diethylcarbamazine 1
Sponsors
SRM Medical College Hospital
Eligibility
Inclusion criteria
Inclusion criteria: seasonal allergic rhinitis mild to moderate bronchial asthma not on inhalers
Exclusion criteria
Exclusion criteria: cardiac, hepatic, renal disorder nasal polyps nasal or oral steroids last 1 month, severe bronchial asthma on inhalers, allergic to montelukast, fexofenadine and diethylcarbamazine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diethylcarbamazine 100 mg twice a day for 21 days along with Montelukast 10mg and fexofenadine 120mg combination for 14 days can reduce pharmacotherapy need in next 3 months This group patients will have more effective control of signs and symptoms copared to other group where only montelukast and fexofenadine was used.Timepoint: At the end of 6 weeks of starting therapy both groups will be assessed with Total nasal score with questionannire and diganostic nasal endoscopy to assess the response of therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| reduces need for steroidal nasal spray in group of patients who are on trial of diethylcarbamzine 100mg twice a day as Serum IgE levels will reduce with Absolute eosinophil counts at 3 weeks of starting therapyTimepoint: At 6 weeks of starting therapy in both groups Serum IgE levels & absolute eosinophil counts are measured. | — |
Countries
India
Contacts
Public ContactMalarvizhi Ravisankar
SRM Medical College Hospital and Research Centre
Outcome results
None listed